Finanzas de United-Guardian Inc (UG)UGUnited-Guardian Inc

United-Guardian Inc (UG) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Pharmaceutical, accounting for 47.2% of total sales, equivalent to $1.47M. Other significant revenue streams include Cosmetic Ingredients and Medical. Understanding this composition is critical for investors evaluating how UG navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, United-Guardian Inc maintains a gross margin of 49.73%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 24.26%, while the net margin is 23.44%. These profitability ratios, combined with a Return on Equity (ROE) of 21.35%, provide a clear picture of how effectively UG converts its operational activities into shareholder value.

In the context of the broader market, UG competes directly with industry leaders such as LOOP and HTOO. With a market capitalization of $32.85M, it holds a leading position in the sector. When comparing efficiency, UG's gross margin of 49.73% stands against LOOP's -46.93% and HTOO's 29.82%. Such benchmarking helps identify whether United-Guardian Inc is trading at a premium or discount relative to its financial performance.

United-Guardian's total revenue for Q2 2026 was $3,108,267, showing a slight increase from the previous quarter, but a significant decrease from the same quarter last year. The gross margin stands at 49.73%, which is relatively stable but lower than previous quarters, indicating potential pressure on profitability.